Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: Association to disease stage and grade and comparison to CA125 and HE4

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  O'Shannessy, Daniel J ^a   Somers, Elizabeth B ^a   Palmer, Leslie M ^a   Thiel, Robert P ^b   Oberoi, Pankaj ^c   Heath, Ryan ^c   Marcucci, Lisa ^d  

^a Morphotek Inc   (United States)

^b THIEL Statistical Consultants   (United States)

^c Meso Scale Discovery   (United States)

^d Frontage Laboratories Inc   (United States)

Author keywords

CA125; Folate receptor alpha; FRA; HE4; Megakaryocyte potentiating factor; Mesothelin; MPF; MSLN; Serous ovarian cancer; Serum biomarker

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; FOLATE RECEPTOR 1; HE4 PROTEIN; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHEMOLUMINESCENCE; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

EID: 84876073350     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-29     Document Type: Article

References (74)

1. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Gynecol Oncol 2004 95 9 15
2. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Cancer Epidemiol Biomarkers Prev 2009 18 1365 1372
3. Factors influencing serum CA125II levels in healthy postmenopausal women. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ, Cancer Epidemiol Biomarkers Prev 2001 10 489 493
4. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Maggino T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, Gynecol Oncol 1994 54 117 123
5. The role of CA-125 in the management of ovarian cancer. Markman M, Oncologist 1997 2 6 9
6. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Cancer Res 2005 65 2162 2169
7. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Galgano MT, Hampton GM, Frierson HF Jr, Mod Pathol 2006 19 847 853
8. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Cancer Res 2003 63 3695 3700
9. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Gynecol Oncol 2008 110 374 382
10. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Gynecol Oncol 2008 110 196 201
11. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R, Clin Chem 2011 57 1534 1544
12. Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. Hellstrom I, Hellstrom KE, Expert Opin Med Diagn 2011 5 227 240
13. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Clin Cancer Res 2004 10 3291 3300
14. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Hellstrom I, Hellstrom KE, Adv Exp Med Biol 2008 622 15 21
15. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Gynecol Oncol 2008 108 402 408
16. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Cancer Epidemiol Biomarkers Prev 2008 17 2480 2487
17. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De VP, Am J Respir Crit Care Med 2010 181 620 625
18. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Clin Cancer Res 2011 17 1181 1189
19. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, J Clin Oncol 2010 28 3316 3322
20. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. Yamaguchi N, Hattori K, Oh-Eda M, Kojima T, Imai N, Ochi N, The Journal of Biological Chemisty 1994 269 805 808
21. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. Kojima T, Oh-Eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, J Biol Chem 1995 270 21984 21990
22. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Cancer Sci 2006 97 928 932
23. Soluble members of the mesothelin / megakaryocyte potentiating factor family are detectable in sera from patients with ovarian cancer. Scholler N, Fu N, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I, PNAS 1999 96 11531 11536
24. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Chang K, Pastan I, Proc Natl Acad Sci U S A 1996 93 136 140
25. Binding of ovanian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. Rump A, Marikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, The Journal of Biological Chemisty 2004 279 9190 9198
26. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Mol Cancer 2006 5 50
27. Mesothelin targeted cancer immunotherapy. Hassan R, Ho M, Eur J Cancer 2008 44 46 53
28. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Ordonez NG, Mod Pathol 2003 16 192 197
29. Mesothelin-family proteins and diagnosis of mesothelioma. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Kierk N, Lancet 2003 362 1612 1616
30. Early detection of ovarian cancer. Badgwell D, Bast RC Jr, Dis Markers 2007 23 397 410
31. HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection. Fritz-Rdzanek A, Grzybowski W, Beta J, Durczynski A, Jakimiuk A, Oncol Lett 2012 4 385 389
32. Hollevoet K, Speeckaert MM, Decavele AS, Vanholder R, van Meerbeeck JP Delanghe JR: Mesothelin Levels in Urine are Affected by Glomerular Leakage and Tubular Reabsorption. Clin Lung Cancer 2012
33. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN, Asian Pac J Cancer Prev 2010 11 111 116
34. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Cancer Epidemiol Biomarkers Prev 2006 15 1014 1020
35. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Gynecol Oncol 2007 106 490 497
36. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Clin Cancer Res 2006 12 4225 4231
37. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, Oncol Rep 2008 20 1375 1380
38. Early detection of ovarian cancer. Das PM, Bast RC Jr, Biomarker Medicine 2008 2 291 303
39. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. O'Shannessy DJ, Somwar R, Maltzman J, Smale R, Fu Y-S, SpringerPlus 2012 1 22
40. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Cancer Res 1992 52 3396 3401
41. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA, Cancer Res 1992 52 6708 6711
42. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, Int J Cancer Suppl 1994 8 89 95
43. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Ross JF, Chaudhuri PK, Ratnam M, Cancer 1994 73 2432 2443
44. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Wu M, Gunning W, Ratnam M, Cancer Epidemiol Biomarkers Prev 1999 8 775 782
45. The alpha folate receptor is highly activated in malignant pleural mesothelioma. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D, J Thorac Cardiovasc Surg 2001 121 225 233
46. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP, Anal Biochem 2005 338 284 293
47. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R, Hum Pathol 2008 39 498 505
48. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. Buist MR, Molthoff CF, Kenemans P, Meijer CJ, J Clin Pathol 1995 48 631 636
49. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Boerman OC, van Niekerk CC, Makkink K, Hanselaar TG, Kenemans P, Poels LG, Int J Gynecol Pathol 1991 10 15 25
50. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R, Ann Surg Oncol 2008 15 889 899
51. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G, Anticancer Res 2008 28 3567 3572
52. Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Veggian R, Fasolato S, Menard S, Minucci D, Pizzetti P, Regazzoni M, Tumori 1989 75 510 513
53. Overexpression of folate binding protein in ovarian cancers. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M, Int J Cancer 1997 74 193 198
54. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Toffoli G, Russo A, Gallo A, Cernigoi C, Miotti S, Sorio R, Int J Cancer 1998 79 121 126
55. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Gynecol Oncol 2008 108 619 626
56. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, PLoS One 2009 4 6292
57. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. O'Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, Oncotarget 2012 3 414 425
58. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Stein R, Goldenberg DM, Mattes MJ, Int J Cancer 1991 47 163 169
59. Expression of Folate Receptor Alpha (FRA) in gynecologic malignancies and its relationship to the tumor type. O'Shannessy DJ, Somers EB, Smale R, Fu Y-S, Int J Gyne 2013 In press
60. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Crane LM, Arts HJ, van OM, Low PS, van der Zee AG, van Dam GM, Cell Oncol (Dordr) 2012 35 9 18
61. Characterization of the human folate receptor alpha via novel antibody-based probes. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Oncotarget 2011 2 1227 1243
62. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Clin Cancer Res 2005 11 5840 5846
63. Clinical and Biological Applications of ECL. Debad J, Glezer EN, Leland JK, Sigal GB, Wohlstadter J, Electrogenerated Chemiluminescence New York: Marcel Dekker, Bard AJ, 2004 359 396
64. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, Gynecol Oncol 2012 125 65 69
65. New tumor markers: CA125 and beyond. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Int J Gynecol Cancer 2005 15 Suppl 3 274 281
66. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Gynecol Oncol 2005 99 267 277
67. Potential markers for detection and monitoring of ovarian cancer. Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A, J Oncol 2011 201 1 475983
68. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, J Thorac Oncol 2012 7 1618 1621
69. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. Lorusso PM, Edelman MJ, Bever SL, Forman KM, Pilat M, Quinn MF, J Clin Oncol 2012 30 4011 4016
70. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Clin Cancer Res 2010 16 5288 5295
71. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Kurman RJ, Shih IM, Hum Pathol 2011 42 918 931
72. Megalin binds and mediates cellular internalization of folate binding protein. Birn H, Zhai X, Holm J, Hansen SI, Jacobsen C, Christensen E, FEBS J 2005 272 4423 4430
73. Urinary concentrations of human epidydimis secretory protein 4 (he4) in the diagnosis of ovarian cancer: a case- control study. Macuks R, Baidekalna I, Donina S, Asian Pac J Cancer Prev 2012 13 4695 4698
74. Serum tumour markers in patients with chronic kidney disease. Xiaofang Y, Yue Z, Xialian X, Zhibin Y, Scand J Clin Lab Invest 2007 67 661 667